Sarepta Therapeutics (SRPT) – Management Comments
-
Sarepta stock jumps on FDA nod for ELEVIDYS gene therapy
-
Sarepta Therapeutics (SRPT) Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to SRPT Stock Lookup